- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Malvern Today
By the People, for the People
Aclaris Therapeutics Upgraded to 'Hold' by Wall Street Zen
Analysts see potential in biotech firm's dermatology pipeline
Apr. 4, 2026 at 5:14am
Got story updates? Submit your updates here. ›
An extreme close-up of the complex financial infrastructure that powers the stock market, hinting at the unseen forces driving investment decisions.Malvern TodayWall Street Zen, an investment research firm, has upgraded its rating on Aclaris Therapeutics (NASDAQ: ACRS) from 'sell' to 'hold' in a new research note. The upgrade comes as the clinical-stage biopharmaceutical company continues to advance its pipeline of novel small-molecule therapies for dermatological conditions and rare disorders.
Why it matters
Aclaris Therapeutics has been working to develop a portfolio of promising dermatology drugs, which could provide new treatment options for patients. The upgrade by Wall Street Zen suggests that analysts see potential value in the company's pipeline, despite previous concerns.
The details
In the research note, Wall Street Zen cited Aclaris' progress on several key programs, including ATI-50002 for molluscum contagiosum, ATI-50003 for common warts, ATI-1501 for pruritic disorders, and ATI-450 for inflammatory indications. The analysts believe these candidates could gain traction in their respective markets if they continue to advance through clinical trials.
- Wall Street Zen issued the research note on Saturday, April 4, 2026.
- Aclaris Therapeutics reported its latest quarterly earnings on Thursday, February 26, 2026.
The players
Wall Street Zen
An investment research firm that provides analysis and ratings on publicly traded companies.
Aclaris Therapeutics
A clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies for dermatological diseases and related rare disorders.
What’s next
Investors will be closely watching Aclaris Therapeutics' progress on its key pipeline programs, particularly as the company prepares to report additional data and milestones in the coming months.
The takeaway
The upgrade by Wall Street Zen suggests that analysts see potential value in Aclaris Therapeutics' dermatology-focused pipeline, which could provide new treatment options for patients if the company's drug candidates continue to advance successfully.
